Computational investigation of the binding mode of bis(hydroxylphenyl)arenes in 17β-HSD1: molecular dynamics simulations, MM-PBSA free energy calculations, and molecular electrostatic potential maps
暂无分享,去创建一个
[1] J. Brosens,et al. Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice. , 2010, The American journal of pathology.
[2] Janet M Thornton,et al. The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. , 2009, Chemico-biological interactions.
[3] N. J. Bush. Advances in hormonal therapy for breast cancer. , 2007, Seminars in oncology nursing.
[4] R. Hartmann,et al. 6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5alpha reductases types 1 and 2. , 2000, European journal of medicinal chemistry.
[5] M. Negri,et al. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). , 2008, Journal of medicinal chemistry.
[6] W. Kohn,et al. Self-Consistent Equations Including Exchange and Correlation Effects , 1965 .
[7] G. Rastelli,et al. Assessing Protein Kinase Selectivity with Molecular Dynamics and MM‐PBSA Binding Free Energy Calculations , 2011, Chemical biology & drug design.
[8] V. Hornak,et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.
[9] G. Scuseria,et al. Gaussian 03, Revision E.01. , 2007 .
[10] Y. Tremblay,et al. Androgenic and estrogenic 17β-hydroxysteroid dehydrogenase/17-ketosteroid reductase in human ovarian epithelial tumors: evidence for the type 1, 2 and 5 isoforms , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[11] H. Tutill,et al. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. , 2008, Endocrine-related cancer.
[12] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[13] V. Adamo,et al. Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] J. Zupan,et al. REPRESENTATION OF MOLECULAR ELECTROSTATIC POTENTIALS BY TOPOLOGICAL FEATURE MAPS , 1994 .
[15] R. Hartmann,et al. Development of a biological screening system for the evaluation of highly active and selective 17β-HSD1-inhibitors as potential therapeutic agents , 2009, Molecular and Cellular Endocrinology.
[16] T. Halgren. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular‐interaction energies and geometries , 1999, Journal of computational chemistry.
[17] Richard D. Taylor,et al. Improved protein–ligand docking using GOLD , 2003, Proteins.
[18] J. Adamski,et al. Recent advances in 17beta-hydroxysteroid dehydrogenases , 2009, The Journal of Steroid Biochemistry and Molecular Biology.
[19] R. Hartmann,et al. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. , 2008, Journal of medicinal chemistry.
[20] Michael Feig,et al. MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology. , 2004, Journal of molecular graphics & modelling.
[21] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[22] P A Komesaroff,et al. Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2. , 2002, The Journal of clinical endocrinology and metabolism.
[23] P. Kollman,et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.
[24] R. Hartmann,et al. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases. , 2010, Journal of medicinal chemistry.
[25] Jack Snoeyink,et al. Nucleic Acids Research Advance Access published April 22, 2007 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007 .
[26] M. Negri,et al. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. , 2009, Journal of medicinal chemistry.
[27] Giulio Rastelli,et al. Fast and accurate predictions of binding free energies using MM‐PBSA and MM‐GBSA , 2009, J. Comput. Chem..
[28] Takashi Suzuki,et al. In situ estrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology , 2009, Pathology international.
[29] R. Hartmann,et al. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. , 2008, Bioorganic & medicinal chemistry.
[30] J. D. Doll,et al. Generalized Langevin equation approach for atom/solid-surface scattering: General formulation for classical scattering off harmonic solids , 1976 .
[31] B. Husen,et al. New inhibitors of 17β-hydroxysteroid dehydrogenase type 1 , 2006, Molecular and Cellular Endocrinology.
[32] Y. Miyoshi,et al. Involvement of up‐regulation of 17β‐hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers , 2001, International journal of cancer.
[33] M. Poutanen,et al. Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme , 2006, Molecular and Cellular Endocrinology.
[34] H. Sasano,et al. 7β-hydroxysteroid Dehydrogenase Type 1 and Type 2 in Human Breast Carcinoma: a Correlation to Clinicopathological Parameters , 2022 .
[35] A. Becke. Density-functional thermochemistry. III. The role of exact exchange , 1993 .
[36] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[37] Andrew L. Lee,et al. Dynamic dysfunction in dihydrofolate reductase results from antifolate drug binding: modulation of dynamics within a structural state. , 2009, Structure.
[38] O. Stål,et al. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. , 2001, Cancer research.
[39] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[40] A. Romano,et al. Increased production of 17beta-estradiol in endometriosis lesions is the result of impaired metabolism. , 2009, The Journal of clinical endocrinology and metabolism.
[41] A. Jansson. 17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer , 2009, The Journal of Steroid Biochemistry and Molecular Biology.
[42] M. Negri,et al. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. , 2010, Bioorganic & medicinal chemistry.
[43] T. Key,et al. Oestrogen exposure and breast cancer risk , 2003, Breast Cancer Research.
[44] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[45] H. Tutill,et al. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design. , 2008, Bioorganic & medicinal chemistry.
[46] J. Bartlett,et al. Hormonal therapy for postmenopausal breast cancer: the science of sequencing , 2007, Breast Cancer Research and Treatment.
[47] R. Hartmann,et al. Structure–activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors , 2009, Molecular and Cellular Endocrinology.
[48] M. Poutanen,et al. In vivo mouse model for analysis of hydroxysteroid (17β) dehydrogenase 1 inhibitors , 2009, Molecular and Cellular Endocrinology.
[49] David L Mobley,et al. The Confine-and-Release Method: Obtaining Correct Binding Free Energies in the Presence of Protein Conformational Change. , 2007, Journal of chemical theory and computation.
[50] Fernand Labrie,et al. The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology , 1997, Steroids.
[51] Sheng-Xiang Lin,et al. Human estrogenic 17beta-hydroxysteroid dehydrogenase: predominance of estrone reduction and its induction by NADPH. , 1999, Biochemical and biophysical research communications.
[52] R. Hartmann,et al. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17β-Hydroxysteroid Dehydrogenase (17β-HSD) type 1 and type 2 , 2009, Molecular and Cellular Endocrinology.
[53] P. Kollman,et al. Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices , 1998 .
[54] M. Recanatini,et al. Insights in 17β-HSD1 Enzyme Kinetics and Ligand Binding by Dynamic Motion Investigation , 2010, PloS one.
[55] B. Brooks,et al. Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .
[56] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[57] Tingjun Hou,et al. Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..
[58] T. Darden,et al. Molecular dynamics simulations of biomolecules: long-range electrostatic effects. , 1999, Annual review of biophysics and biomolecular structure.
[59] G. Hodgen,et al. Endometriosis: role of ovarian steroids in initiation, maintenance, and suppression. , 1980, Fertility and sterility.
[60] T. Darden,et al. A smooth particle mesh Ewald method , 1995 .
[61] F. Grodstein,et al. Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study , 2001, Annals of Internal Medicine.
[62] Takashi Suzuki,et al. 17β‐Hydroxysteroid Dehydrogenases in Human Breast Cancer , 2009, Annals of the New York Academy of Sciences.
[63] R. Hartmann,et al. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. , 2008, Journal of medicinal chemistry.
[64] B. Potter,et al. 17β‐hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone‐dependent breast cancer , 2008 .
[65] S. Gobec,et al. Inhibitors of 17-Hydroxysteroid Dehydrogenase Type 1 , 2008 .
[66] O. Stål,et al. 17β-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer , 2005, British Journal of Cancer.
[67] D. Poirier. Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases. , 2009, Anti-cancer agents in medicinal chemistry.
[68] Annamaria Lilienkampf,et al. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core. , 2009, Journal of medicinal chemistry.
[69] P. Hohenberg,et al. Inhomogeneous Electron Gas , 1964 .
[70] T Darden,et al. New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. , 1999, Structure.
[71] J. Simard,et al. Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. , 2000, Journal of molecular endocrinology.